Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
AbbVie ends development of IL-1 asset in ulcerative colitis
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.
Gabrielle Masson
Jul 31, 2025 12:32pm
Abivax aces phase 3 colitis trials as end of cash runway looms
Jul 23, 2025 6:30am
Sanofi shows how $500M IBD bet compares to Merck, Roche rivals
Feb 24, 2025 8:11am
Odyssey, Sionna join band of biotechs braving the IPO waters
Jan 21, 2025 5:27am
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
Dec 17, 2024 10:30am
OSE's ulcerative colitis prospect improves symptoms in phase 2
Jul 24, 2024 8:23am
